Capital orders for Stereotaxis more than doubled in the second quarter, sending shares of the medical device maker up 24 percent Tuesday.
Capital orders climbed to $10.2 million in the quarter, the company said, with half those orders coming from North America.
Stereotaxis makes devices to help doctors treat coronary artery disease and arrhythmia. The company reported a total of $10.6 million in revenue in the first quarter, and a Thomson Reuters poll shows that analysts are expecting $14.3 million in total revenue in the second quarter.
The company said capital orders rose 42 percent compared to the first quarter. Stereotaxis will report full second-quarter results after the market closes on Aug. 2.
Shares of Stereotaxis Inc. climbed 77 cents to $3.92 in afternoon trading.